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Abstract
Background: The screening of peptide-based epitopes has been studied extensively for the purpose of developing
therapeutic antibodies and prophylactic vaccines that can be potentially useful for treating cancer and infectious
diseases such as influenza virus, malaria, hepatitis B, and HIV. To improve the efficacy of antibody production by
epitope-based immunization, researchers evaluated liposomes as a means of delivering vaccines; they also formulated
adjuvants such as flagella and CpG-DNA to enhance the magnitude of immune responses. Here, we provide a potent
method for peptide-based epitope screening and antibody production without conventional carriers.
Results: We present that a particular form of natural phosphodiester bond CpG-DNA encapsulated in a specific
liposome complex (Lipoplex(O)) induces potent immunomodulatory activity in humans as well as in mice.
Additionally, Lipoplex(O) enhances the production of IgG2a specific to antigenic protein in mice. Most importantly,
immunization of mice with several peptides co-encapsulated with Lipoplex(O) without carriers significantly induces
each peptide-specific IgG2a production in a TLR9-dependent manner. A peptide-specific monoclonal antibody
produced against hepatocellular carcinoma-associated antigen has functional effects on the cancer cells.
Conclusions: Our overall results show that Lipoplex(O) is a potent adjuvant and that complexes of peptide and
Lipoplex(O) are extremely useful for B cell epitope screening and antibody production without carriers. Therefore,
our strategy may be promptly used for the development of therapeutic antibodies by rapid screening of potent B
cell epitopes.
Background
Synthetic oligodeoxynucleotides (ODNs) and bacterial
DNA containing unmethylated CpG dinucleotides
flanked by specific base sequences (CpG-DNA) have sig-
nificant immunomodulatory effects on B lymphocytes,
macrophages, dendritic cells, and natural killer cells
[1-4]. Experimental evidence suggests that CpG-DNA
induces the regulation of Th1/Th2 immune responses,
antigen-presenting cell activity, and immunoglobulin (Ig)
isotype switching [5-7]. Therefore, CpG-DNA has gained
attention for its potential use as an immune adjuvant and
in therapeutics for allergic and infectious diseases [8,9].
Phosphorothioate-modified types of CpG-DNA (PS-
ODN), which are resistant to nuclease activity and can be
efficiently delivered into cells [10,11], have been utilized in
clinical applications [9]. The immunomodulatory activities
of PS-ODN are enhanced by liposome-encapsulation
[12-14]. However, several studies have suggested that PS-
ODN induces backbone-related side effects, such as transi-
ent splenomegaly [15], lymphoid follicle destruction [16],
arthritis [17], and PS-ODN-specific IgM production [18] in
PS-ODN-treated mice. Investigators consequently devel-
oped phosphodiester bond CpG-DNA (PO-ODN) as a nat-
ural counterpart of PS-ODN to induce optimal innate
immune responses without severe side effects. In contrast
to PS-ODN, the immunomodulatory effects of PO-ODN
are found only in mouse cells and not in human cells [19].
However, induction of an effective immune response has
been reported in human cells stimulated with PO-ODN
and non-CpG-DNA encapsulated in cationic liposomes
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any medium, provided the original work is properly cited.such as N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylam-
monium methylsulfate (DOTAP) and lipofectin [20,21].
In previous studies, we screened natural PO-ODN with
immunomodulatory activity from Mycobacterium bovis
genomic DNA [22]. Our experimental analyses demon-
strated that a potent PO-ODN, namely MB-ODN 4531
(O), which contains three CpG motifs, has functional
effects as a powerful adjuvant for the induction of Ag-
driven Th1 responses without causing severe side effects
in mice [18,22]. In this study, we compared the ability of
MB-ODN 4531(O) encapsulated in several different lipo-
somes to stimulate immune responses in human and
mice cells, finding that MB-ODN 4531(O) encapsulated
in a phosphatidyl-b-oleoyl-g-palmitoyl ethanolamine
(DOPE):cholesterol hemisuccinate (CHEMS) complex
(Lipoplex(O)) was most potent in human as well as in
mice. Furthermore, we extended the research to the
selection of a synthetic peptide-based B cell epitope and
revealed that complexes of several peptides and Lipoplex
(O) without carriers significantly enhanced the each pep-
tide-specific IgG production depending on TLR9. In this
study, we identified a B cell epitope peptide from hepato-
cellular carcinoma (HCC)-specific transmembrane 4
superfamily member 5 (TM4SF5) protein [23] that
potently induced epitope-specific antibodies. We also
noticed that the monoclonal antibody produced by
immunization with a complex consisting of antigenic
peptide (TM4SF5R2-3) and Lipoplex(O) had functional
effects on cells expressing the antigen. Our results sug-
gest that the selection of B cell epitope can be facilitated
by the delivery of the DOPE:CHEMS complex and by
the adjuvant effect of MB-ODN 4531(O). Our strategy
may be promptly used for the development of epitope-
based peptide vaccines and production of therapeutic
antibodies.
Results
Effects of CpG-DNA encapsulated in liposomes on IL-8
promoter activation
To identify the conditions driving the effective immuno-
modulatory activity of PO-ODN in humans, we encapsu-
lated MB-ODN 4531(O) in several different liposomes and
compared the abilities of the complexes to stimulate
immune responses in human and mouse cells. First, we
confirmed that IL-8 promoter was activated in human and
mouse cells treated with CpG-DNA encapsulated in lipo-
somes. When PO-ODN was encapsulated in a DOTAP,
DOPE:CHEMS (1:1 ratio) complex, or 1,2-dioctadecanoyl-
sn-glycero-3-phosphocholine (DSPC):CHEMS:phosphati-
dylethanolamine-poly(ethylene glycol) (PEG-PE) (6:4:0.3
ratio) complex, it activated the IL-8 promoter in human
RPMI 8226 cells as well as in mouse RAW 264.7 cells. To
confirm the significance of CpG motif of MB-ODN 4531
(O), we synthesized MB-ODN 4531GC(O) which has GpC
dinucleotides instead of CpG dinucleotides in the MB-
ODN 4531(O) sequence. The luciferase activity was not
enhanced by MB-ODN 4531GC(O) in the mouse and
human cell lines, proving that the IL-8 promoter activa-
tion is CpG sequence-dependent (Figure 1). The highest
activity was produced by PO-ODN encapsulated in DOPE:
CHEMS (1:1 ratio) complex. Here, we named MB-ODN
4531(O) encapsulated in DOPE:CHEMS (1:1 ratio) com-
plex as Lipoplex(O) (Table 1).
Enhanced intracellular uptake of CpG-DNA by
encapsulation in a DOPE:CHEMS complex
Depending on the delivery vehicles, CpG-DNA can elicit
enhanced intracellular uptake, endosomal localization,
and biological activity of CpG-DNA [20]. To chase the
process, we used FACS to analyze the intracellular
uptake of FITC-labeled MB-ODN 4531(O). As shown in
Figure 2a, the intracellular uptake of MB-ODN 4531(O)
is enhanced markedly when the MB-ODN 4531(O) is
encapsulated in a DOPE:CHEMS complex (Lipoplex
(O)). TLR9-mediated cytokine production by CpG-DNA
requires acidification and maturation of endosomes [24].
As shown in Figure 2b, pretreatment with chloroquine,
an inhibitor of endosomal processing, inhibits the IL-8
promoter activation induced by Lipoplex(O). These
results confirm that the efficacy of PO-ODN can be
enhanced by encapsulation in a DOPE:CHEMS complex
via the improved intracellular uptake of CpG-DNA and
endosomal localization.
Effects of CpG-DNA encapsulated in DOPE:CHEMS
complex on cytokine production
To determine the effects of Lipoplex (O) on cytokine pro-
duction, we treated human peripheral blood mononuclear
cells (PBMCs) or mouse splenocytes with 50 μg/ml of
nonencapsulated CpG-DNA or Lipoplex(O) for 12 h. The
CpG-DNA failed to induce the release of IL-6, IL-12, and
IFN-g in human PBMCs when treated as a free form. In
contrast, Lipoplex(O) induced the release of IL-6, IL-12,
and IFN-g in a CpG sequence-dependent manner from
human PBMCs and mouse splenocytes (Figure 3a and 3b).
When MB-ODN 4531(O) or Lipoplex(O) was applied in
vivo, Lipoplex(O) induced secretion of IL-12 and IFN-g for
much longer periods than MB-ODN 4531(O) did (Figure
3c). It may be related with the enhanced stability of MB-
ODN 4531(O) in vivo when encapsulated in DOPE:
CHEMS complex. As expected, the immunomodulatory
activity of Lipoplex(O) was entirely TLR9-dependent; cyto-
kine production was not found in TLR9-/- mice (Figure
3d). These results confirm that cytokine secretion was
increased by Lipoplex(O) in a CpG sequence- and TLR9-
dependent manner.
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CHEMS complex
To evaluate the adjuvant activity of CpG-DNA encapsu-
lated in liposomes, we immunized BALB/c mice with
different combinations of hen egg lysozyme (HEL), MB-
ODN 4531(O), and DOPE:CHEMS complex (Figure 4).
Immunization of BALB/c mice with HEL only or with
HEL encapsulated in DOPE:CHEMS complex did not
induce HEL-specific IgG. Immunization with a mixture
of HEL and MB-ODN 4531(O), there was increased
production of HEL-specific total IgG, which can be
resulted from the adjuvant effect of MB-ODN 4531(O).
Most importantly, immunization with a complex con-
sisting of HEL and Lipoplex(O) (Lipoplex(O) + HEL)
resulted in a markedly greater abundance of HEL-speci-
fic total IgG than other mice. Amount of HEL-specific
total IgG induced by a complex of HEL and Lipoplex
(O) was approximately four times higher than that
induced by a mixture of HEL and MB-ODN 4531(O)
(Figure 4a). Titers of HEL-specific total IgG also show
similar results (Figure 4b). Next, we confirmed the IgG
isotype of anti-HEL-specific antibodies. Remarkably,
immunization with a complex of HEL and Lipoplex(O)
or a mixture of HEL and MB-ODN 4531(O) induced
more IgG2a than IgG1, indicating that MB-ODN 4531
(O) affects isotype profile independently of encapsula-
tion (Figure 4a). However, immunization with a mixture
of HEL and incomplete Freund’s adjuvant (IFA) induced
higher level of IgG1 than IgG2a. Based on the result
from the LipoplexGC(O) plus HEL, we confirmed that
Lipoplex(O)-mediated HEL-specific antibody production
is CpG sequence-dependent which is in accordance with
Table 1 Abbreviations used in this study.
Abbreviations Descriptions
4531(O) MB-ODN 4531(O)
4531GC(O) MB-ODN 4531GC(O)
DOPE:CHEMS Complex consisting of DOPE:CHEMS (1:1 ratio)
Lipoplex(O) Complex of MB-ODN 4531(O) encapsulated with DOPE:CHEMS
DOPE:CHEMS + HEL (OVA or peptide) Complex of HEL (OVA or peptide) encapsulated with DOPE:CHEMS
Lipoplex(O) + HEL (OVA or peptide) Complex of HEL (OVA or peptide) and MB-ODN 4531(O) co-encapsulated with DOPE:CHEMS
4531(O) + HEL (OVA or peptide) Mixture of MB-ODN 4531(O) and HEL (OVA or peptide)
LipoplexGC(O) + HEL (OVA or peptide) Complex of HEL (OVA or peptide) and MB-ODN 4531GC(O) co-encapsulated with DOPE:CHEMS
Control
DOTAP
Lipofectamine
(1:1 ratio)
(6:4 ratio)
(1:0 ratio)
(0:1 ratio)
DOPE:CHEMS
DSPC:Chol
DSPC:CHEMS:PEG-PE
Chol:DOPE:PEG-PE
Dc-Chol:DOPE:PEG-PE
RPMI 8226 RAW 264.7
0 5 10 15
Fold activation (pIL-8-Luc)
05 10
Fold activation (pIL-8-Luc)
PBS
4531(O)
4531GC(O)
PBS
4531(O)
4531GC(O)
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Figure 1 Effect of CpG-DNA encapsulated in different liposome complexes on IL-8 promoter activation. Human RPMI 8226 cells (left) and
mouse RAW 264.7 cells (right) were transiently transfected with pIL-8-Luc for 24 h and stimulated with indicated liposomes or CpG-DNA (PO-
ODN) encapsulated in the indicated liposome complexes for 12 h. Cultures were harvested and assayed for luciferase assay. The luciferase
activity of the cells was measured in relative light units, and this value was normalized to Renilla activity. The results are represented as fold
activation and compared to the PBS-treated control. Each bar represents Mean ± SD values of three experiments. *P < 0.05, **P < 0.01 (vs PBS
control).
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experiments with another antigen ovalbumin (OVA),
Lipoplex(O) plus OVA appears to induce more IgG2a
and hence a more balanced response than IFA plus
OVA as shown in Figure 4c and 4d.
Th1-dominated humoral immune response induced by
peptide epitope and CpG-DNA encapsulated in DOPE:
CHEMS complex
As the potent adjuvant effect of Lipoplex(O) was identi-
fied in Figure 4, we applied this system to the screening
of B cell epitopes against tumor-specific antigen. Specifi-
cally, we aimed to screen B cell epitopes originated from
human tetraspanin transmembrane 4 superfamily mem-
ber 5 of human HCC (hTM4SF5) (GenBank:
NP_003954) [23]. Six candidate peptide sequences were
selected from extracellular domain of hTM4SF5 protein
on the basis of their hydrophilicity, hydrophobicity, sec-
ondary structure, antigenicity index as described in
“Methods” (Table 2).
First, we screened the B cell epitopes of hTM4SF5
protein. We analyzed the amounts of IgG in the serum
of BALB/c mice injected i.p. with complexes of each
predicted hTM4SF5 peptide and Lipoplex(O). As shown
in Figure 5a, the production of peptide-specific IgG was
most enhanced by a complex consisting of hTM4SF5R2-
3 peptide and Lipoplex(O). Anti-hTM4SF5R2-3-specific
antibodies were mostly composed of IgG2a (Figure 5b
and 5c). We evaluated the kinetics of IgG production in
immunized mice in response to the complex of
hTM4SF5R2-3 peptide and Lipoplex(O). The mice
produced larger amounts of peptide-specific IgG (IgG2a)
during the secondary and tertiary responses (Figure 5d).
W h e nt h em i c ew e r ei m m u n i z e dw i t hh T M 4 S F 5 R 2 - 3
peptide and MB-ODN 4531(O) co-encapsulated in other
liposomes, the production of peptide-specific IgG was
much lower, which demonstrates the superior effect of
Lipoplex(O) (Figure 5e). However, MB-ODN 4531GC
(O) containing a reversal sequence of the CG dinucleo-
tide lost its ability to stimulate production of IgG (Fig-
ure 5f). IgG production by hTM4SF5R2-3 peptide and
Lipoplex(O) was dependent on TLR9, whereas IgG pro-
duction by antigen and IFA was not (Figure 6). These
results indicate that the complex of hTM4SF5R2-3 pep-
tide and Lipoplex(O) without carriers significantly
enhanced production of peptide-specific IgG2a in a CpG
sequence-dependent and TLR9-dependent manner.
Functional effect of anti-hTM4SF5 monoclonal antibody
on hepatocellular carcinoma cells in vitro
The expression of TM4SF5 induced uncontrolled
growth of human HCC cells via loss of contact inhibi-
tion [23]. To evaluate the functional effects of IgG pro-
duced by immunization with the complex of
hTM4SF5R2-3 peptide and Lipoplex(O), we screened
monoclonal antibody against hTM4SF5R2-3 peptide and
confirmed its specificity by competition ELISA using
hTM4SF5R2-3 peptide (Figure 7a). We then analyzed
the expression of hTM4SF5 in human HCC cell lines
and evaluated the monoclonal antibody-mediated
hTM4SF5 targeting in the cells. The expression of
hTM4SF5 was detected in Huh-7 and SNU-761 cells at
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Figure 2 Effect of CpG-DNA encapsulated in DOPE:CHEMS on intracellular uptake and endosomal localization of CpG-DNA. (a) Effect of
DOPE:CHEMS (1:1 ratio) encapsulation on uptake of CpG-DNA was analyzed by FACS. RPMI 8226 cells and RAW 264.7 cells were treated with
FITC-labeled CpG-DNA or FITC-labeled CpG-DNA encapsulated in DOPE:CHEMS complex for 10 min. Intracellular uptake of CpG-DNA was
measured by FACS analysis. 4531(O), FITC-labeled MB-ODN 4531(O); Lipoplex(O), FITC-labeled MB-ODN 4531(O) encapsulated in DOPE:CHEMS
complex. (b) Involvement of endosomal acidification in IL-8 promoter activation induced by CpG-DNA encapsulated in DOPE:CHEMS complex
was confirmed by chloroquine pretreatment. Luciferase activity in was measured in relative light units, and the value was normalized to Renilla
activity. The results are represented in terms of fold activation and are compared to the PBS-treated control. Each bar represents Mean ± SD
values obtained from three experiments. **P < 0.01 (vs PBS control).
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Figure 3 Production of cytokines in hPBMC and mouse splenocytes by CpG-DNA encapsulated in DOPE:CHEMS complex. The levels of
IL-6, IL-12, and IFN-g were measured by ELISA assay (a, b and d) or a Cytokine Bead Array kit (c). hPBMC (a), splenocytes from BALB/c mice (b),
and splenocytes from BALB/c TLR9 knockout mice (TLR9-/-, n = 3/group) (d) were stimulated with LPS, free MB-ODN (oligo only) or MB-ODN
encapsulated in a DOPE:CHEMS (1:1 ratio) complex for 24 h and the culture supernatants were harvested. The levels of IL-6, IL-12, and IFN-g were
measured with an ELISA assay. (c) BALB/c mice (n = 4/group) were injected i.p with MB-ODN 4531(O) or Lipoplex(O), and sera from the mice
were harvested at the indicated times after injection. The concentration of IL-12p70 and IFN-g in the serum was determined by using a Cytokine
Bead Array kit. Each bar and graph represents Mean ± SD values obtained from three or four mice. These experiments were performed 2 times
with similar results. *P < 0.05, **P < 0.01 (vs PBS control).
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Page 5 of 15the mRNA by RT-PCR (Figure 7b) and protein levels by
immunoblotting and FACS analysis with the hTM4SF5-
specific monoclonal antibody (Figure 7c and 7d). To
investigate the effect of the anti-hTM4SF5R2-3 peptide
monoclonal antibody on cell growth, we performed
MTT assay. The growth of Huh-7 cells expressing
hTM4SF5 was markedly delayed by antibody treatment.
However, there was no significant reduction in the
growth of SNU-739 cells, which did not express
Table 2 Candidate epitopes of hTM4SF5
Proteins Peptides Sequences Location Length
hTM4SF5R1 NGETSWTNTNHLSL 32-45 14
hTM4SF5R2-1 RNGPRCLMNGEWGY 113-126 14
hTM4SF5 hTM4SF5R2-2 GEWGYHFEDTAGAY 122-135 14
hTM4SF5R2-3 NRTLWDRCEAPPRV 138-151 14
hTM4SF5R2-4 WDRCEAPPRVVPWN 142-155 14
hTM4SF5R2-5 GAYLLNRTLWDRCEA 133-147 15
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Figure 4 Production of Th1-associated HEL (or OVA) antigen-specific IgG induced by CpG-DNA encapsulated in DOPE:CHEMS complex. (a)
Amounts of anti-HEL-specific total IgG and IgG isotypes. (b) Titers of anti-HEL-specific total IgG, anti-HEL-specific IgG1, and anti-HEL-specificI g G 2 a .( c )
Amounts of anti-OVA-specific total IgG and IgG isotypes. (d) Titers of anti-OVA-specific total IgG, anti-OVA-specific IgG1, and anti-OVA-specificI g G 2 a .
Three BALB/c mice were immunized with one of the following combinations: 50 μg of HEL (or OVA); 50 μgo fM B - O D N4 5 3 1 ( O )a n d5 0μg of HEL (or
OVA); 50 μg of HEL (or OVA) with DOPE:CHEMS; 50 μg of Lipoplex(O) and 50 μg of HEL (or OVA); or 50 μg of Lipoplex GC(O) and 50 μgo fH E L ;I F A
and 50 μg of HEL (or OVA). The sera were collected, and the total IgG and IgG isotypes were assayed with an ELISA kit. Each bar represents Mean ± SD
values obtained from three mice. This experiment was performed 3 times with similar results. **P <0 . 0 1( vs IFA + HEL (or OVA)).
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Figure 5 Selection of epitopes and production of epitope-specific IgG by a complex of peptide and Lipoplex(O). (a-c) Selection of B cell
epitopes from hTM4SF5 protein by immunization with complexes consisting of each predicted hTM4SF5 peptide and Lipoplex(O). BALB/c mice
(n = 3/group) were immunized with complexes consisting of each peptide (hTM4SF5R1, hTM4SF5R2-1, hTM4SF5R2-2, hTM4SF5R2-3, hTM4SF5R2-
4, and hTM4SF5R2-5) and Lipoplex(O) (Lipoplex(O) + peptide). (a) Amounts of anti-each peptide-specific total IgG. (b) Amounts of anti-
hTM4SF5R2-3 peptide-specific IgG isotypes. (c) Titers of anti-hTM4SF5R2-3 peptide-specific IgG isotypes. (d) The kinetics of IgG production. BALB/
c mice (n = 3/group) were immunized with the complex of hTM4SF5R2-3 peptide and Lipoplex(O). BALB/c mice were injected i.p. with
hTM4SF5R2-3 peptide and Lipoplex(O) complex. The sera were collected one day before each injection and 10 days after final injection, and an
ELISA kit was used to assay amounts of the peptide-specific total IgG, IgG1, IgG2a and IgM were assayed with an ELISA kit. (e) Induction of
DOPE:CHEMS encapsulation-dependent peptide-specific IgG production. BALB/c mice (n = 5/group) were immunized with 50 μg of hTM4SF5R2-
3 peptide and 50 μg of MB-ODN 4531(O) coencapsulated in a DOPE:CHEMS (1:1 ratio), DSPC:Chol (45:55 ratio), DSPC:CHEMS:PEG-PE (6:4:0.3 ratio),
Chol:DOPE:PEG-PE (4:6:0.06 ratio), or Dc-Chol:DOPE:PEG-PE (4:6:0.06 ratio) complex. The sera were collected, and amounts of anti-hTM4SF5R2-3
peptide-specific total IgG were assayed with an ELISA kit. (f) Effect of GC dinucleotide and phosphorothioate backbone modification. BALB/c
mice (n = 5/group) were immunized with 50 μg of hTM4SF5R2-3 peptide and one of the following complexes (50 μg): Lipoplex(O), or
LipoplexGC(O). The sera were collected, and amounts of peptide-specific total IgG were assayed with an ELISA kit. The results are expressed as a
Mean ± SD of three or five mice. These experiments were performed 3 times with similar results. **P < 0.01 (vs PBS control).
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Page 7 of 15hTM4SF5 (Figure 8a). The population of cells in S phase
was also reduced in Huh-7 cells but not SNU-739 cells
(Figure 8b) To further investigate the effects of the anti-
hTM4SF5R2-3 peptide antibody on DNA synthesis, the
BrdU incorporation assay was performed. As shown in
Figure 8c, the rate of DNA synthesis in Huh-7 cells
treated with anti-hTM4SF5R2-3 peptide monoclonal
antibody was weakly affected one day after treatment
and further suppressed in three days by approximately
40% compared to normal IgG treated-Huh-7 cells
(Figure 8c). In contrast, there was no effect in SNU-739
cells. Next, we investigated whether the anti-hTM4SF5R2-
3 peptide antibody induces apoptotic response of Huh-7
cells. As shown in Figure 8d, the treatment of anti-
hTM4SF5R2-3 peptide antibody did not lead to an
increase in the number of apoptotic cells containing dou-
ble-stranded DNA breaks in Huh-7 cells or SNU-739 cells.
Therefore, we conclude that the anti-hTM4SF5R2-3 pep-
tide antibody has anti-proliferative effect rather than pro-
apoptotic effect in Huh-7 cells. These results confirm that
the monoclonal antibody produced by immunization with
hTM4SF5R2-3 peptide and Lipoplex(O) complex was use-
ful for hTM4SF5 protein detection and antibody-mediated
hTM4SF5 targeting in HCC cells.
Discussion
The application of CpG-DNA to therapeutics can be opti-
mized via sequence rearrangement and backbone modifi-
cation [25,26]. The recognition of CpG-DNA by TLR9
varies from mice to human immune cells due to a 24% dif-
ference at the amino acid level between the TLR9 mole-
cules of mice and humans [8,19]. PS-ODN stimulates the
human and mouse immune systems in several ways: effi-
cient uptake into cells, endosomal acidification and
maturation, and enhanced recognition by TLR9 in endo-
somes and lysosomes [24]. However, PO-ODN, which
exhibits immunomodulatory activity in mice, shows poor
activity in hPBMCs [8,27]. Recently, the cationic liposome
DOTAP was used as a vehicle for delivery; it was found to
improve the uptake of PO-ODN as well as the production
of IFN-a in hPBMCs [20]. Here, we examined the effects
of liposome-encapsulated PO-ODN on cytokine promoter
activation and cytokine production in mouse and human
cells. After stimulation with PO-ODN encapsulated in
liposomes such as DOTAP, DOPE:CHEMS complex, and
DSPC:CHEMS:PEG-PE complex, the IL-8 promoter was
significantly activated in human and mouse cells and max-
imum activity was seen with PO-ODN encapsulated in
DOPE:CHEMS complex (Lipoplex(O)) (Figure 1).
Recent studies by several investigators have shown that
CpG-DNA has functional effects as a Th1-responsive
adjuvant and that its potent adjuvant effects are enhanced
by liposome encapsulation [12,14]. In this report, we
f o u n dt h a tL i p o p l e x ( O )s u r p a s s e dI F Ai nt e r m so ft h e
potency of antigen-specific IgG production and Th1-type
immune responses in mice (Figure 4): higher titers and
more IgG2a. This outstanding adjuvant effect of Lipoplex
(O) in mice is very interesting and suggests that Lipoplex
(O) could have a promising adjuvant effect in humans.
The potency of Lipoplex(O) seems to be derived from the
improved intracellular uptake of CpG-DNA and endoso-
mal localization (Figure 2), and enhanced or prolonged
production of cytokines such as IL-6, IL-12, and IFN-g
(Figure 3).
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Figure 6 Induction of TLR9-dependent epitope-specific IgG production by a complex of peptide and Lipoplex(O). BALB/c mice (WT) and
BALB/c TLR9 knockout mice (TLR9-/-) (n = 3/group) were immunized with hTM4SF5R2-3 peptide (50 μg/mouse) and Lipoplex(O) complex
(Lipoplex(O) + TM4SF5R2-3) (a), IFA with 50 μg of HEL (b), or IFA with hTM4SF5R2-3 peptide (b). The sera were collected, and amounts of the
peptide-specific total IgG were assayed with an ELISA kit. The results are expressed as a Mean ± SD of three mice. This experiment was
performed 2 times with similar results. *P < 0.05 (vs control mice).
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Page 8 of 15The screening of synthetic peptide-based epitopes has
been studied extensively for the purpose of developing
therapeutic antibodies and vaccines that have potential
as prophylactics for cancer and infectious diseases such
as influenza virus, malaria, hepatitis B, and HIV [28-30].
Although peptide vaccines have been actively studied in
various animal models, their efficacy in the treatment of
humans is limited. To improve the efficacy of peptide
vaccines, researchers have evaluated liposomes as a
means of delivering vaccines [13,31-33]. Adjuvants such
as flagella [34] and CpG-DNA [13] have also been for-
mulated in order to enhance the magnitude of the
immune responses. In this study, we performed peptide-
based epitope screening and used complex of synthetic
peptide and Lipoplex(O) without carriers to produce
antibodies that act against hTM4SF5 in human HCC.
We successfully screened a potent B cell epitope
(hTM4SF5R2-3 peptide) from hTM4SF5 (Figure 5). We
f o u n dt h a tL i p o p l e x ( O )s u r p a s s e dI F Aa n do t h e rf o r m s
of liposome-encapsulated CpG-DNA in terms of the
potency of peptide-specific IgG production and Th1-
type immune responses in mice (Figure 5 and 6). There-
fore, our data offer a powerful tool for practical use:
Lipoplex(O) is a potentially applicable universal adjuvant
for peptide-based epitope screening and antibody pro-
duction, and it obviates the need for other adjuvants
and carriers. However, further study is needed to inves-
tigate whether or not IgG production induced by a
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Figure 7 Detection of TM4SF5 by anti-hTM4SF5 monoclonal antibody produced by hTM4SF5R2-3 peptide and Lipoplex(O) complex.
(a) Reactivity of anti-hTM4SF5R2-3 monoclonal antibody with hTM4SF5R2-3 peptide. hTM4SF5R2-3 peptide was immobilized on the plate, and
competitive ELISA was performed using increasing amounts of soluble hTM4SF5R2-3 peptide. (b) Expression of hTM4SF5 mRNA in the human
hepatocarcinoma cell lines. The expression level of hTM4SF5 mRNA was analyzed by RT-PCR with cDNAs from the indicated cell lines and
normal hepatocytes. (c-d) Detection of hTM4SF5 by anti-hTM4SF5R2-3 peptide monoclonal antibody in human hepatocarcinoma cell lines.
(c) The expression of hTM4SF5 protein was analyzed by immunoblotting with anti-hTM4SF5R2-3 peptide mAb in human hepatocarcinoma cell
lines. (d) The hepatocarcinoma cell lines were stained with anti-hTM4SF5R2-3 peptide monoclonal antibody and then FITC-conjugated antibody
to anti-mouse IgG, and analyzed with a FACScan flow cytometer. Normal mouse IgG was used as a control.
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Figure 8 Functional effects of anti-hTM4SF5 monoclonal antibody produced by immunization with hTM4SF5R2-3 peptide and
Lipoplex(O) complex. (a) Effect of anti-hTM4SF5R2-3 peptide monoclonal antibody on cell growth. Cell growth was measured by MTT assay.
Each bar is expressed as a Mean + SD of three experiments. **P < 0.01 (vs normal IgG control). (b) Effect of anti-hTM4SF5R2-3 peptide
monoclonal antibody on cell cycle. The cells were stained with propidium iodide in PBS containing RNase and analyzed by flow cytometry. (c)
Effect of anti-hTM4SF5R2-3 peptide monoclonal antibody on proliferation. The DNA synthesis activity was monitored by BrdU incorporation
assay. Each bar is expressed as a Mean ± SD of three experiments. *P < 0.05, **P < 0.01 (vs normal IgG control). (d) Effect of anti-hTM4SF5R2-3
peptide monoclonal antibody on apoptosis. FACSCalibur flow cytometer was used to analyze cells containing fluorescein-labeled double strand
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similar results.
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Page 10 of 15complex of B cell epitope and Lipoplex(O) is dependent
on MHC type, CD4
+ cells and Th1 differentiation and if
a novel mechanism is involved (Figure 9).
Examination of the IgG isotype levels demonstrates
that the peptide and Lipoplex(O) complex induced
higher levels of IgG2a than IgG1, indicating a predomi-
nant Th1 response. It is well-known that differential
induction of Th1-type or Th2-type immune response by
a vaccine is important for protective immunity in speci-
fied infectious diseases. For example, several studies
have reported that formalin-inactivated human respira-
tory syncytial virus (RSV) vaccine was not effective
because of its ability to induce an allergy-like Th2
immune response against the virus infection [35-37].
Therefore, our formulation may be applied as an effec-
tive adjuvant for peptide-based RSV B cell epitope
screening and effective RSV vaccine: the formulation
may decrease susceptibility to RSV and induce Th1-
biased or balanced Th1/Th2 adaptive immune response
leading to the production of neutralizing antibodies.
This study suggest that Lipoplex(O) is a potent adju-
vant and that complexes of epitope and Lipoplex(O)
without carriers are extremely useful for B cell epitope
screening and peptide-specific antibody production. As
our novel vaccine strategy using Lipoplex(O) and syn-
thetic peptide does not require protein antigen produc-
tion and carrier conjugation, it is cost effective and
enables rapid application. For example, TM4SF5 protein
has gained attention as a target for HCC therapy since
it is overexpressed in HCC [23]. TM4SF5 is also impor-
tant in HCC formation by inducing morphological elon-
gation, epithelial-mesenchymal transition, abnormal cell
growth in multilayers in vitro, and tumor formation in
vivo. But there was no report regarding epitope-specific
monoclonal antibody against TM4SF5 yet. As indicated
in a detailed study, we successfully produced monoclo-
nal antibody without production of recombinant protein.
The anti-hTM4SF5R2-3 peptide-specific antibody can
detect native protein and induce functional changes in
cells expressing TM4SF5 protein, which suggests
possible application in therapeutics (Figure 7 and 8). We
are currently investigating whether or not anti-
hTM4SF5R2-3 peptide-specific antibody can reduce
HCC tumor formation in a xenograft mouse model after
Huh-7 cells have been injected. We applied our strategy
to monomeric peptide and produced antibody recogniz-
ing native protein in this study. Whether our technology
can also be applied to conformationally dependent epi-
topes or poorly immunogenic peptides is to be deter-
mined in the future.
Conclusions
Our overall results show that Lipoplex(O) is a potent
adjuvant and that complexes of epitope and Lipoplex(O)
without carriers are extremely useful for B cell epitope
screening and peptide-specific antibody production.
Therefore, our strategy may be promptly used for the
development of therapeutic antibodies by rapid screen-
ing of potent B cell epitopes (Figure 10).
Methods
ODNs and reagents
ODNs were obtained from Samchully Pharm (Seoul,
Korea) and GenoTech (Daejeon, Korea). MB-ODN 4531
consisted of 20 bases containing three CpG motifs (under-
lined): AGCAGCGTTCGTGTCGGCCT. The sequence of
MB-ODN 4531 used in this study was phosphodiester
bond (O). MB-ODN 4531GC(O) is a derivative of MB-
ODN 4531(O) with one of its CG sequences reversed to
GC (underlined): AGCAGGCTTCGTGTCGGCCT.
When necessary, biotin or fluorescent tags were conju-
gated to the 3’ end of each ODN. The endotoxin content
of the ODNs was less than 1 ng/mg of ODN when mea-
sured by Limulus amebocyte assay (Whittaker Biopro-
ducts, Walkersville, MD, USA). To block the endosomal
localization of CpG-DNA, we pretreated the cells with
chloroquine (10 μM) for 1 h before stimulation with CpG-
DNA or liposome-encapsulated CpG-DNA.
Preparation of protein (or peptide) and CpG-DNA co-
encapsulated in liposome complexes
The liposomes CHEMS, Chol, DOPE, and DSPC were
purchased from Sigma-Aldrich (St. Louis, MO, USA). 3b-
(N-(N’,N’-dimethylaminoethane)-carbamoyl)cholesterol
(DC-Chol) and PEG-PE were obtained from Avanti-Polar
Lipids (Alabaster, AL, USA). Complexes of CpG-DNA
and protein (or peptide) with DOTAP (Roche, Indianapo-
lis, IN, USA), lipofectamine (Invitrogen, Carlsbad, CA,
USA) or lipofectin (Invitrogen) were prepared in accor-
dance with the manufacturer’s specifications. Liposome
complexes consisting of protein (or peptide) and CpG-
DNA co-encapsulated with DOPE:CHEMS, DSPC:Chol
(55:45 ratio), DSPC:CHEMS:PEG-PE (6:4:0.3 ratio), Chol:
DOPE:PEG-PE (4:6:0.06 ratio) or Dc-Chol:DOPE:PEG-PE
Protein antigen
or 
B cell epitopes
+  Lipoplex(O) Efficient antibody
production
Th1 differentiation-dependent?
Endosomal processing of CpG-ODN
Intracellular uptake of CpG-ODN 
In vivo stability of CpG-ODN
Production of cytokines
MHC-dependent?
CD4-dependent?
Novel mechanism?
Figure 9 Possible mechanisms involved in the adjuvant effect
of Lipoplex(O). The activity of Lipoplex(O) confirmed in this study
are checked above the arrow. The issues to be determined in the
future are shown below the arrow.
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Page 11 of 15(4:6:0.06 ratio) were prepared as reported previously [38]
with minor modifications. Briefly, DOPE and CHEMS
were mixed in ethanol at a molar ratio of 1:1, or as indi-
cated in the individual experiments, evaporated with
nitrogen gas to make a solvent-free lipid film, and resus-
pended in a mixture containing equal volumes of water-
soluble CpG-DNA and protein (or peptide), followed by
vigorous stirring at room temperature for 30 min. After
adjusting the pH to 7.0, the Lipoplex solution was slightly
sonicated for 30 s with a sonicator. We then filtered the
solution with a 0.22 μm filter and freeze-thawed it three
times with liquid nitrogen.
Transfection and luciferase assays
Transfection and luciferase assays were performed as
previously described [26]. For transfection with an IL-8
promoter-reporter construct, we used FuGENE 6 Trans-
fection Reagent (Roche). RPMI 8226 cells (human B cell
line) and RAW 264.7 cells (mouse macrophage cell line)
were treated with CpG-DNA (5 μg/ml) or CpG-DNA
encapsulated in liposomes for 12 h, or as indicated in the
individual experiments.
Uptake of CpG-DNAs
RPMI 8226 cells and RAW 264.7 cells were plated in
24-well plates for 24 h and then treated with FITC-
labeled CpG-DNA or FITC-labeled CpG-DNA encap-
sulated in DOPE:CHEMS complex for 10 min. Intra-
cellular uptake of CpG-DNA was measured by FACS
analysis with a FACSCalibur cytometer (BD Bios-
ciences, San Diego, CA, USA) as reported previously
[39].
Measurement of cytokines
To measure cytokines, CpG-DNA (5 μg/ml) or CpG-
DNA (5 μg/ml) encapsulated in DOPE:CHEMS complex
was added to splenocytes or hPBMCs, followed by incu-
bation at 37°C with 5% CO2 for 24 h. The cytokine
levels in the culture supernatant were then measured
using commercially available ELISA kits (R&D Systems,
Minneapolis, MN, USA). The amount of cytokines in
the sera was quantified using a cytokine bead array kit
for mouse inflammatory cytokines (CBA; BD Bios-
ciences) and a FACSCalibur cytometer equipped with
CellQuestPro and CBA software.
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Figure 10 Schematic diagrams summarizing the experimental process. (a) General overview of experiments and possible applications. (b)
Specific procedure performed in this work and possible applications.
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Page 12 of 15Selection and synthesis of B cell epitope peptides
The putative B cell epitope peptides of hTM4SF5 were
selected on the basis of hydrophilicity values from Par-
ker et al [40], surface accessibility values from Emini
et al [41], b-turn region values from Chou and Fasman
[42], and antigenicity index from Kolaskar and Ton-
gaonkar [43]. The parameters were averaged over six
amino acid residues and the regions above the threshold
value 1.0 were chosen for each prediction factor (http://
tools.immuneepitpoe.org/main/index.html). To screen B
cell epitope, we selected 6 candidates from the putative
B cell epitope peptides, which are located in the extra-
cellular domain of hTM4SF5 (Table 2). The peptides
were synthesized using an automated peptide synthesi-
zer (Peptron III-R24, Peptron, Daejeon, Korea). The
peptides were purified by reverse-phase HPLC (Promi-
nence HPLC, Shimadzu Corp., Tokyo, Japan) to purity
greater than 90%. The peptide was identified using a
mass spectrometer (HP 1100 Series LC/MSD, Hewlett-
Packard, Roseville, CA, USA).
Mice and immunization
Mice were maintained under specific-pathogen-free con-
ditions. We purchased four-week-old male BALB/c (H-
2
b) mice from Central Lab. Animal, Inc. (Seoul, Korea),
BALB/c TLR9 knockout mice from Oriental Bioservice,
Inc. (Kyoto, Japan). Our animal studies were approved
by the Institutional Animal Care and Use Committee of
Hallym University (Hallym 2009-47). On three occasions
at 10 day intervals, the mice were injected intraperitone-
ally (i.p.) with 50 μg of HEL, OVA, or peptides (50 μg)
supplemented with either 50 μgo fC p G - D N Ao rC p G -
DNA encapsulated in liposomes.
Antigen-specific Ig ELISA assay
Mouse sera were obtained by orbital bleeding before
each injection as well as by sacrifice 10 days after final
injection and then stored at -70°C. To measure the
amounts of total IgG, IgG1, and IgG2a, 96-well immu-
noplates were coated with 5 μg/ml of each protein or
peptide and then blocked with 0.05% of Tween-20 in
PBS (PBST) containing 1% BSA. The sera were diluted
to 1:450 with PBST and added to the wells of each
plate. To measure the titers of total IgG, IgG1 and
IgG2a, the sera were added to the top row of each plate,
and serial 1:3 dilutions in PBST were then placed into
subsequent rows. The plates were incubated for 2 h at
room temperature and washed with PBST. Then, rat
anti-mouse biotinylated secondary antibodies (total IgG,
IgG1, or IgG2a) (BD Biosciences) were added to the
wells and incubated for 1 h, followed by addition of
streptavidin conjugated with horseradish peroxidase for
30 min. A colorimetric assay was developed with a TMB
substrate solution (Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA), and we used a Spectra Max
250 microplate reader (Molecular Devices, Sunnyvale,
CA, USA) to measure the absorbance at 450 nm. Anti-
body titers were defined as the reciprocal serum dilution
yielding half-maximal signal.
Production of mouse anti-hTM4SF5 monoclonal antibody
On three occasions at 10 day intervals, BALB/c mice
were injected i.p. with hTM4SF5R2-3 peptide (50 μg) and
MB-ODN 4531(O) (50 μg) co-encapsulated in DOPE:
CHEMS complex. In accordance with standard hybri-
doma technique, we then screened hybridoma cells that
produce anti-hTM4SF5R2-3 peptide-specific monoclonal
antibody [44]. Anti-hTM4SF5R2-3 peptide monoclonal
antibody (IgG2a) was purified from the ascites fluid by
protein A column chromatography.
Reactivity of mouse anti-hTM4SF5 monoclonal antibody:
Competitive ELISA assay
To measure the titers of anti-TM4SF5R2-3 peptide
monoclonal antibody, we coated 96-well immunoplates
with 10 μg/ml of human TM4SF5R2-3 peptides and
then blocked them with PBST containing 1% BSA. The
antibodies were added to the top row of each plate, and
serial 1:4 dilutions in PBST were then placed into subse-
quent rows. For competition assay, diluted antibodies
were preincubated with the indicated amounts of each
peptide for 30 min and then added to the wells of each
plate. The plates were incubated for 2 h at room tem-
perature, washed with PBST, and then incubated with
anti-IgG antibody conjugated with horseradish peroxi-
dase for 2 h. The colorimetric assay was developed with
a TMB substrate solution (Kirkegaard and Perry Labora-
tories), and we used a Spectra Max 250 microplate
reader (Molecular Devices, Sunnyvale, CA, USA) to
measure the absorbance at 450 nm.
Cell culture
The human B cell line RPMI 8226, mouse macrophage
cell line RAW 264.7, and the human hepatoma cell lines
Huh-7 and HepG2 were obtained from ATCC. The
human hepatocellular cell lines SNU-398, SNU-423,
SNU-739, and SNU-761 were obtained from the Korean
Cell Line Bank (Seoul, Korea). The cells were maintained
in RPMI 1640 medium containing 10% FBS. Human nor-
mal hepatocyte cells (Promo Cell, Heidelberg, Germany)
were maintained as the vendor suggested. All cells were
cultured at 37°C in an atmosphere of 95% air and 5%
CO2.
Detection of TM4SF5 expression
To analyze hTM4SF5 expression, we performed RT-
PCR, immunoblotting, and FACS analysis. Total RNAs
were extracted with an RNeasy Mini Kit (Qiagen,
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as described previously [26]. The standard PCR reaction
was performed for 25 cycles with the following primer
sets: human b-actin, 5’-GGGTCAGAAGGATTCC-
TATG-3’ and 5’-CCTTAATGTCACGCACGATTT-3’
(500 bp); hTM4SF5, 5’-AGCTTGCAAGTCTGGCT-
CAT-3’ and 5’-GCTGGATCCCACACAGTACT-3’ (408
bp); The expression of hTM4SF5 protein was confirmed
by immunoblotting and FACS analysis with purified
anti-hTM4SF5 monoclonal antibody.
MTT assay
The growth of cells treated with anti-hTM4SF5 mono-
clonal antibody (5 μg/ml) was determined by MTT
assay with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tet-
razolium bromide (MTT, Sigma-Aldrich) solution as
previously described [45].
BrdU proliferation assay
To assess the cell proliferation after treatment with anti-
hTM4SF5 monoclonal antibody, Huh-7 and SNU-739
cells were seeded into a 96-well microplate at a density of
10
5 cells/well. The cells were treated with anti-hTM4SF5
monoclonal antibody (5 μg/ml) for the indicated time
periods. Subsequently, cells were fixed, washed, and incu-
bated with primary and secondary antibodies according
to the instruction of CycLex BrdU Cellular ELISA Kit
(MBL International, Woburn, USA). The immune com-
plexes were developed with a substrate solution, and we
used a Spectra Max 250 microplate reader (Molecular
Devices, Sunnyvale, CA, USA) to measure the absorbance
at 450 nm.
Cell cycle analysis
To analyze DNA content, we incubated the cells in a
solution of propidium iodide (20 μg/ml) in PBS contain-
ing RNase (200 μg/ml). The cells were stained at room
temperature for 30 min and analyzed using FACSCali-
bur cytometer (BD Biosciences).
TUNEL assay
We performed terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) assay in
accordance with the manufacturer’s specifications (Pro-
m e g a ,M a d i s o n ,W I ,U S A ) .B r i e f l y ,H u h - 7a n dS N U - 7 3 9
cells were placed in a complete medium for 24 h before
being treated with anti-hTM4SF5 monoclonal antibody (5
μg/ml) for 3 days. The cells were fixed with 4% parafor-
maldehyde and permeabilized with 0.2% Triton X-100 for
5 min at room temperature, and end-labeled with TdT
using the DeadEnd™ Fluorometric TUNEL system. The
DNase I treatment served as a control of TUNEL-positive
cells. After washing with PBS-T, cells were observed with
FACSCalibur cytometer (BD Biosciences).
Abbreviations
CpG-DNA: synthetic DNA containing immunostimulatory CpG motifs;
CHEMS: cholesterol hemisuccinate; DOPE: phosphatidyl-β-oleoyl-γ-palmitoyl
ethanolamine; Lipoplex(O): MB-ODN 4531(O) encapsulated in DOPE:CHEMS
(1:1 ratio) complex; PO-ODN: natural phosphodiester CpG-DNA; hTM4SF5:
human tetraspanin transmembrane 4 superfamily member 5.
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